The Medical Potential of Antimicrobial Peptides from Insects
Antimicrobial peptides (AMPs) are peptide-based effector molecules produced by the innate immune system to combat microbes. Insects produce the broadest repertoire of AMPs, and their potent antimicrobial activity in vitro and in vivo has promoted their development as alternatives to conventional antibiotics, in an attempt to address the threat of multidrug-resistant pathogens. Here we discuss current obstacles that hinder the therapeutic development of novel insect-derived AMPs, including potential cytotoxic, immunogenic and allergenic side effects, and the high costs of large-scale production. These challenges may be overcome by the falling costs of synthetic peptide analogs and the heterologous production of recombinant peptides in insect cells or plants (molecular pharming). Insect AMPs offer a promising alternative for the treatment of skin, eye and lung infections, and could also restore the susceptibility of multidrug-resistant pathogens to conventional antibiotics when used as combinatorial treatments. Insect AMPs can also be used as templates for the rational design of peptide mimetics to overcome the drawbacks of natural therapeutic peptides..
Medienart: |
Artikel |
---|
Erscheinungsjahr: |
2017 |
---|---|
Erschienen: |
2017 |
Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
---|---|
Enthalten in: |
Current topics in medicinal chemistry - 17(2017), 5, Seite 554-575 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Miray Tonk [VerfasserIn] |
---|
Links: |
---|
BKL: |
---|
doi: |
10.2174/1568026616666160713123654 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
OLC1991531346 |
---|
LEADER | 01000caa a2200265 4500 | ||
---|---|---|---|
001 | OLC1991531346 | ||
003 | DE-627 | ||
005 | 20230512013835.0 | ||
007 | tu | ||
008 | 170303s2017 xx ||||| 00| ||eng c | ||
024 | 7 | |a 10.2174/1568026616666160713123654 |2 doi | |
028 | 5 | 2 | |a PQ20170301 |
035 | |a (DE-627)OLC1991531346 | ||
035 | |a (DE-599)GBVOLC1991531346 | ||
035 | |a (PRQ)b2281-715f33d4c33adacd991aa1ed5fa07ff745b884bc548ad180bb83df0aa329d13d0 | ||
035 | |a (KEY)0446467220170000017000500554medicalpotentialofantimicrobialpeptidesfrominsects | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 540 |q DNB |
084 | |a PHARM |2 fid | ||
084 | |a 44.40 |2 bkl | ||
100 | 0 | |a Miray Tonk |e verfasserin |4 aut | |
245 | 1 | 4 | |a The Medical Potential of Antimicrobial Peptides from Insects |
264 | 1 | |c 2017 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
338 | |a Band |b nc |2 rdacarrier | ||
520 | |a Antimicrobial peptides (AMPs) are peptide-based effector molecules produced by the innate immune system to combat microbes. Insects produce the broadest repertoire of AMPs, and their potent antimicrobial activity in vitro and in vivo has promoted their development as alternatives to conventional antibiotics, in an attempt to address the threat of multidrug-resistant pathogens. Here we discuss current obstacles that hinder the therapeutic development of novel insect-derived AMPs, including potential cytotoxic, immunogenic and allergenic side effects, and the high costs of large-scale production. These challenges may be overcome by the falling costs of synthetic peptide analogs and the heterologous production of recombinant peptides in insect cells or plants (molecular pharming). Insect AMPs offer a promising alternative for the treatment of skin, eye and lung infections, and could also restore the susceptibility of multidrug-resistant pathogens to conventional antibiotics when used as combinatorial treatments. Insect AMPs can also be used as templates for the rational design of peptide mimetics to overcome the drawbacks of natural therapeutic peptides. | ||
700 | 0 | |a Andreas Vilcinskas |4 oth | |
773 | 0 | 8 | |i Enthalten in |t Current topics in medicinal chemistry |d Hilversum [u.a.] : Bentham Science Publ., 2001 |g 17(2017), 5, Seite 554-575 |w (DE-627)338770283 |w (DE-600)2064823-6 |w (DE-576)435515160 |x 1568-0266 |7 nnns |
773 | 1 | 8 | |g volume:17 |g year:2017 |g number:5 |g pages:554-575 |
856 | 4 | 1 | |u http://dx.doi.org/10.2174/1568026616666160713123654 |3 Volltext |
856 | 4 | 2 | |u http://www.eurekaselect.com/openurl/content.php?genre=article&issn=1568-0266&volume=17&issue=5&spage=554 |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_OLC | ||
912 | |a FID-PHARM | ||
912 | |a SSG-OLC-PHA | ||
912 | |a SSG-OLC-DE-84 | ||
912 | |a SSG-OPC-PHA | ||
912 | |a GBV_ILN_4219 | ||
936 | b | k | |a 44.40 |q AVZ |
951 | |a AR | ||
952 | |d 17 |j 2017 |e 5 |h 554-575 |